A carregar...
Concizumab: a novel anti-TFPI therapeutic for hemophilia
Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7805331/ https://ncbi.nlm.nih.gov/pubmed/33570646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001140 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|